Guggenheim analyst Delma Caiati assumes coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target of $207.00.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $143.18 yesterday.